Biopharma Liver Disease Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Liver Disease Therapeutics
1.1 - About Biopharma Liver Disease Therapeutics sector
Companies in Biopharma Liver Disease Therapeutics discover, develop, and commercialize medicines that treat hepatic disorders spanning viral hepatitis, cholestatic diseases, fatty liver, and cirrhosis complications. They deliver clinically proven therapies that halt disease progression, improve liver function, and reduce hospitalizations. Strategic buyers in this category focus on differentiated mechanisms, robust clinical data, and scalable manufacturing to bring new hepatology treatments to providers, payers, and patients.
Offerings typically include oral small‑molecule regimens for HBV/HCV and hepatic encephalopathy, biologics such as monoclonal antibodies targeting inflammatory and fibrotic pathways, bile‑acid modulators and FXR agonists for cholestatic disease and NASH, antifibrotic agents and FGF21 analogs for metabolic liver disorders, and liver‑targeted siRNA/ASO therapeutics using GalNAc delivery. Companies complement pipelines with clinical development, cGMP manufacturing, pharmacovigilance, and market access services to support approval, labeling, and global launch.
Primary customers include hepatology specialists and liver centers, hospital systems and clinics, and national payers and PBMs. These companies help achieve sustained virologic response in hepatitis, slow or reverse fibrosis progression in NASH, reduce pruritus and cholestasis complications, and lower rates of decompensation and hospitalization. Outcomes translate to improved quality of life, better guideline adherence, and measurable savings in total cost of care.
2. Buyers in the Biopharma Liver Disease Therapeutics sector
2.1 Top strategic acquirers of Biopharma Liver Disease Therapeutics companies
Nimbus Therapeutics
- Description: Provider of structure-based drug discovery services that design precision small-molecule medicines targeting well-validated yet difficult-to-drug proteins across cancer, autoimmune and metabolic diseases, leveraging leading-edge computational chemistry and machine-learning predictive modeling to generate breakthrough clinical candidates.
- Key Products:
- NDI-101150 HPK1 Inhibitor: Highly potent, selective small-molecule HPK1 inhibitor that broadly activates T
- B and dendritic cells to trigger robust antitumor responses, including in checkpoint-resistant tumors and synergizes with anti-PD1 therapy
- WRN Program for MSI-H Cancers: Preclinical small-molecule program targeting WRN helicase to exploit synthetic lethality in microsatellite-instable tumors, aiming for precision oncology treatments
- Computational Drug Design Platform: Physics-based and AI-driven platform combining computational chemistry, machine learning and predictive modeling to design best-in-class molecules for hard targets, speeding candidate discovery
- Precision Small-Molecule Pipeline: Portfolio of oncology, autoimmune and metabolic disease candidates created through structure-guided design, each selected for strong biological validation and potential to impact broad patient populations.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Liver Disease Therapeutics sector
M&A buyer group 1: Gastroenterology
Galapagos
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology research and drug development focused on creating transformational medicines for high-unmet medical needs across the U.S., Europe and Asia. The company combines science, technology and collaboration to build a deep pipeline of best-in-class therapies and employs an innovative decentralized cell-therapy manufacturing platform to deliver treatments efficiently from lab to patient.
- Key Products:
- Decentralized Cell Therapy Manufacturing Platform: Enables near-patient production of cell therapies, integrating lab-to-clinic workflows to accelerate treatment delivery and improve access for patients
- GLPG5101 CAR-T Therapy: Investigational CAR-T cell treatment for relapsed/refractory mantle cell lymphoma, granted FDA RMAT status to provide durable responses in blood cancer
- Therapeutic Pipeline: Portfolio of best-in-class drug candidates addressing high unmet medical needs, developed through synergistic science and technology to extend years and quality of life.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Liver Disease Therapeutics sector
3.1 - Buyout funds in the Biopharma Liver Disease Therapeutics sector
2.2 - Strategic buyer groups for Biopharma Liver Disease Therapeutics sector
4 - Top valuation comps for Biopharma Liver Disease Therapeutics companies
4.2 - Public trading comparable groups for Biopharma Liver Disease Therapeutics sector
Valuation benchmark group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.